ARCT
Arcturus Therapeutics Holdings Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+23/100
Last price
13.17
▼ 1.49 (10.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
14.66
Prev close
14.66
Day high
15.04
Day low
12.97
Volume
884.86K
Market cap
$369.50M
P/E (TTM)
—
52W range
5.50 – 24.17
Day trading desk
Gap from prior close
+0.00%
Prior close 14.66
VWAP
13.55
-2.79% from price
Relative volume
0.90×
Normal
Session range
23.36%
12.97 – 16.00
Position in range
7%
Near session low
ATR (14D)
1.41
10.72% of price
Prior day high
15.17
PDH
Prior day low
12.68
PDL
Bid / ask spread
—
Quote not published
Session volume
841.57K
Avg 931.26K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.11%
-7.1%
1M
-17.83%
-19.0%
3M
+78.08%
+73.6%
6M
+52.76%
+34.6%
YTD
+112.07%
+97.8%
1Y
-42.38%
-58.8%
3Y
-49.12%
-131.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARCT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.27M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 15, 25 | SASSINE ANDY H Chief Financial Officer |
BUY | 1.24K | $20.50K | Direct |
| Oct 15, 24 | CHIVUKULA PADMANABH Chief Operating Officer |
SELL | 12.00K | $249.12K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHIVUKULA PADMANABH |
Chief Operating Officer | 435.33K | Sale |
SASSINE ANDY H |
Chief Financial Officer | 221.76K | Purchase |
Fundamentals
Market cap$369.50M
Enterprise value$200.95M
Revenue (TTM)$29.37M
Gross profit$-57.41M
EBITDA$-99.55M
Net income$-93.28M
EPS (TTM)$-2.95
Free cash flow$19.26M
Total cash$191.48M
Total debt$22.93M
Book value / share$6.05
Shares outstanding28.42M
Float26.15M
Short % of float23.93%
Dividend yield0.00%
Beta (5Y)2.48
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.59
PEG ratio—
Price / sales—
Price / book2.15
EV / revenue6.84
EV / EBITDA-2.02
Gross margin-195.50%
Operating margin-863.30%
Profit margin0.00%
Return on equity-46.31%
Return on assets-23.96%
Debt / equity13.35
Current ratio5.88
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $67.22M | $138.39M | $157.75M | $205.75M | -51.4% |
| Operating revenue | $67.22M | $138.39M | $157.75M | $205.75M | -51.4% |
| Research & development | $112.21M | $195.16M | $192.13M | $147.75M | -42.5% |
| Selling, general & admin | $46.08M | $52.82M | $52.87M | $46.07M | -12.8% |
| Total operating expense | $143.48M | $234.06M | $235.95M | $193.58M | -38.7% |
| Operating income | -$76.26M | -$95.67M | -$78.20M | $12.18M | +20.3% |
| Net interest income | $10.10M | $15.20M | $16.59M | -$420.00K | -33.6% |
| Pre-tax income | -$65.78M | -$80.94M | -$27.89M | $10.64M | +18.7% |
| Tax provision | $0 | -$4.00K | $1.83M | $1.29M | +100.0% |
| Net income | -$65.78M | -$80.94M | -$29.73M | $9.35M | +18.7% |
| Net income to common | -$65.78M | -$80.94M | -$29.73M | $9.35M | +18.7% |
| Basic EPS | -2.40 | -3.00 | -1.00 | 0.35 | +20.0% |
| Diluted EPS | -2.40 | -3.00 | -1.00 | 0.35 | +20.0% |
| EBIT | -$65.77M | -$80.94M | -$27.12M | $12.18M | +18.7% |
| EBITDA | -$62.75M | -$77.40M | -$24.16M | $13.70M | +18.9% |
| Basic shares | 27.39M | 27.00M | 26.63M | 26.45M | +1.4% |
| Diluted shares | 27.39M | 27.00M | 26.63M | 27.09M | +1.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $230.91M | $237.03M | $292.00M | $391.88M | — | -2.6% |
| Cash & short-term investments | $230.91M | $237.03M | $292.00M | $391.88M | — | -2.6% |
| Accounts receivable | $5.56M | $3.97M | $32.06M | $2.76M | — | +40.0% |
| Total current assets | $241.45M | $305.98M | $386.59M | $403.33M | — | -21.1% |
| Property, plant & equipment | $27.82M | $36.20M | $40.93M | $44.96M | — | -23.2% |
| Total assets | $271.15M | $344.07M | $429.40M | $450.39M | — | -21.2% |
| Total current liabilities | $36.38M | $65.49M | $81.99M | $126.98M | — | -44.5% |
| Current debt | — | — | — | $60.66M | $22.47M | — |
| Long-term debt | — | — | — | — | $40.63M | — |
| Total debt | $25.00M | $28.55M | $30.22M | $94.75M | — | -12.4% |
| Total liabilities | $57.16M | $103.09M | $150.89M | $180.07M | — | -44.6% |
| Retained earnings | -$514.59M | -$448.81M | -$367.87M | -$338.14M | — | -14.7% |
| Shareholder equity | $213.99M | $240.98M | $278.51M | $270.31M | — | -11.2% |
| Working capital | $205.07M | $240.49M | $304.60M | $276.35M | — | -14.7% |
| Net tangible assets | $213.99M | $240.98M | $278.51M | $270.31M | — | -11.2% |
| Shares issued | 28.41M | 27.00M | 26.83M | 26.55M | — | +5.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$65.78M | -$80.94M | -$29.73M | $9.35M | +18.7% |
| Depreciation & amortisation | $3.02M | $3.54M | $2.96M | $1.53M | -14.6% |
| Stock-based compensation | $25.41M | $37.99M | $34.65M | $30.61M | -33.1% |
| Change in working capital | -$39.20M | -$20.81M | $7.38M | -$12.56M | -88.4% |
| Operating cash flow | -$74.27M | -$59.75M | -$18.10M | $31.99M | -24.3% |
| Capital expenditure | -$230.00K | -$648.00K | -$2.90M | -$7.73M | +64.5% |
| Investing cash flow | -$230.00K | -$648.00K | -$2.90M | -$7.73M | +64.5% |
| Financing cash flow | $13.38M | $5.42M | -$24.09M | -$2.86M | +147.0% |
| Free cash flow | -$74.50M | -$60.40M | -$21.00M | $24.27M | -23.4% |
| End cash position | $232.79M | $293.91M | $348.89M | $393.98M | -20.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $880.00K | $610.00K | $3.08M | $14.15M | $24.51M | — | +44.3% |
| Operating revenue | $880.00K | $610.00K | $3.08M | $14.15M | $24.51M | — | +44.3% |
| Research & development | $17.52M | $21.53M | $24.48M | $23.27M | $29.58M | — | -18.6% |
| Selling, general & admin | $10.99M | $9.46M | $14.03M | $10.40M | $10.34M | — | +16.1% |
| Total operating expense | $26.43M | $29.54M | $34.39M | $30.66M | $36.13M | — | -10.5% |
| Operating income | -$25.55M | -$28.93M | -$31.31M | -$16.51M | -$11.62M | — | +11.7% |
| Net interest income | $1.82M | $1.93M | $1.52M | $3.23M | $2.57M | — | -5.8% |
| Pre-tax income | -$23.79M | -$26.96M | -$29.08M | -$13.45M | -$9.18M | — | +11.8% |
| Tax provision | $0 | — | -$4.00K | $0 | $4.00K | $0 | — |
| Net income | -$23.79M | -$26.96M | -$29.08M | -$13.45M | -$9.18M | — | +11.8% |
| Net income to common | -$23.79M | -$26.96M | -$29.08M | -$13.45M | -$9.18M | — | +11.8% |
| Basic EPS | -0.84 | -0.95 | -1.03 | -0.49 | -0.34 | — | +11.6% |
| Diluted EPS | -0.84 | -0.95 | -1.03 | -0.49 | -0.34 | — | +11.6% |
| EBIT | -$25.55M | -$28.93M | -$20.82M | -$16.51M | -$11.62M | — | +11.7% |
| EBITDA | -$24.90M | -$28.27M | -$20.14M | -$15.75M | -$10.84M | — | +11.9% |
| Basic shares | 28.42M | 28.42M | 28.11M | 27.19M | 27.13M | — | +0.0% |
| Diluted shares | 28.42M | 28.42M | 28.11M | 27.19M | 27.13M | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $191.48M | $211.38M | $230.91M | $180.36M | $196.47M | — | -9.4% |
| Cash & short-term investments | $191.48M | $211.38M | $230.91M | $180.36M | $196.47M | — | -9.4% |
| Accounts receivable | $1.81M | $1.34M | $5.56M | $7.95M | $17.20M | — | +35.0% |
| Total current assets | $197.16M | $216.88M | $241.45M | $249.20M | $274.50M | — | -9.1% |
| Property, plant & equipment | $25.12M | $26.50M | $27.82M | $31.26M | $32.88M | — | -5.2% |
| Total assets | $224.31M | $245.41M | $271.15M | $282.34M | $309.27M | — | -8.6% |
| Total current liabilities | $33.54M | $34.37M | $36.38M | $31.70M | $46.52M | — | -2.4% |
| Long-term debt | — | — | — | — | — | $15.00M | — |
| Total debt | $22.93M | $23.99M | $25.00M | $25.99M | $26.96M | — | -4.4% |
| Total liabilities | $52.50M | $54.05M | $57.16M | $57.78M | $78.22M | — | -2.9% |
| Retained earnings | -$565.34M | -$541.55M | -$514.59M | -$485.51M | -$472.06M | — | -4.4% |
| Shareholder equity | $171.81M | $191.36M | $213.99M | $224.56M | $231.05M | — | -10.2% |
| Working capital | $163.63M | $182.51M | $205.07M | $217.50M | $227.99M | — | -10.3% |
| Net tangible assets | $171.81M | $191.36M | $213.99M | $224.56M | $231.05M | — | -10.2% |
| Shares issued | 28.42M | 28.42M | 28.41M | 27.23M | 27.15M | — | -0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$23.79M | -$26.96M | -$29.08M | -$13.45M | -$9.18M | — | +11.8% |
| Depreciation & amortisation | $643.00K | $658.00K | $682.00K | $763.00K | $779.00K | — | -2.3% |
| Stock-based compensation | $4.23M | $4.33M | $6.82M | $5.73M | $6.20M | — | -2.2% |
| Change in working capital | -$1.06M | $2.57M | $3.39M | -$10.37M | -$3.68M | — | -141.2% |
| Operating cash flow | -$19.91M | -$19.44M | -$16.23M | -$17.15M | -$5.75M | — | -2.4% |
| Capital expenditure | — | — | — | -$181.00K | — | -$137.00K | — |
| Investing cash flow | $18.00K | $34.00K | $88.00K | -$181.00K | $0 | — | -47.1% |
| Financing cash flow | $0 | $16.00K | $11.69M | $1.23M | -$14.73M | — | -100.0% |
| Free cash flow | -$19.91M | -$19.44M | -$16.14M | -$17.33M | -$5.75M | — | -2.4% |
| End cash position | $193.51M | $213.40M | $232.79M | $237.25M | $253.35M | — | -9.3% |
Options analytics
Put / call volume
1.29
Put-heavy session
Put / call open interest
1.22
Positioning, not flow
Max pain
15.00
+15.4% from spot
ATM implied vol
107.4%
Nearest strike to spot
Skew (10% OTM)
-20.7%
Calls bid over puts
Call volume
120
Contracts, this expiry
Put volume
155
Contracts, this expiry
Heaviest call OI
22.50
1.14K contracts
Heaviest put OI
12.50
2.46K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.03 | -0.84 | +18.1% |
| Mar 2026 | -1.01 | -0.95 | +6.3% |
| Dec 2025 | -0.76 | -1.03 | -36.4% |
| Sep 2025 | -0.80 | -0.49 | +38.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.67 | 10 | $8.04M | -53.1% |
| Next quarter | -0.90 | 10 | $5.71M | -20.7% |
| Current year | -3.42 | 10 | $18.64M | -77.3% |
| Next year | -3.62 | 10 | $29.59M | +58.7% |
Analyst targets & ownership
Mean target$23.20
High target$41.00
Low target$9.00
Implied upside76.16%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold2
Sell / Strong sell0 / 0
Held by insiders7.99%
Held by institutions83.08%
Institutions holding192
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.70
-3.88% from price
SMA 20
14.46
-10.11% from price
SMA 50
12.11
+7.36% from price
SMA 100
9.55
+37.95% from price
SMA 200
8.57
+51.73% from price
EMA 12
13.92
-5.41% from price
EMA 26
13.79
-4.46% from price
EMA 50
12.55
+4.92% from price
RSI (14)
46.2
Neutral
MACD (12,26,9)
0.14
Hist -0.35
ATR (14)
1.41
10.86% of price
Realised vol 30D
92.1%
Annualised
Bollinger upper
16.54
20, 2σ
Bollinger lower
12.38
20, 2σ
50 / 200 cross
Golden
12.11 vs 8.57
Trend bias
Above 200
+51.73%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.82
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
92.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-76.1%
Peak to trough
Max drawdown 5Y
-88.4%
Peak to trough
ATR 14
1.41
10.86% of price
Beta (reported)
2.48
5Y monthly, from filing
Short interest
Shares short
5.47M
Prior 6.53M
Change vs prior
-16.2%
Shorts covering
% of float
23.93%
Heavily shorted
% of shares out
19.24%
Against total outstanding
Days to cover
3.7
Liquid
Float
26.15M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 26 | Citigroup | UPGRADE | Neutral | Buy |
| Sep 24, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 2, 26 | Freedom Broker | INITIATED | — | Buy |
| Mar 18, 26 | B. Riley Securities | INITIATED | Neutral | Buy |
| Mar 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Mar 4, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Mar 4, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jan 6, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Nov 13, 25 | Citigroup | MAINTAINED | Neutral | Neutral |
| Nov 11, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Nov 11, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Oct 24, 25 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateNov 16, 2017
Last split1:7
Split dateNov 16, 2017
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-23
Corporate Changes & Voting Matters
8-K · 2026-08-25
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-02
Corporate Changes & Voting Matters
8-K · 2026-06-05
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-24
Corporate Changes & Voting Matters
8-K · 2026-03-03
Headlines
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Zacks · 9d ago
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
MarketBeat · 12d ago
CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls
The Fly · 13d ago
Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8
MT Newswires · 13d ago
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Business Wire · 13d ago
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Business Wire · 19d ago
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Business Wire · 36d ago
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
Zacks · 41d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.